Biotech deals surge to record as fear of missing out grips Big Pharma

Biopharma M&A activity accelerated significantly in the first half of 2026, with an aggregate deal value reaching $130 billion, almost equaling the $133 billion total for the entire year of 2025. This surge is attributed to Big Pharma's need to acquire innovative assets, particularly within oncology (41% of deal value) and immunology (19%), to address impending patent expirations and pipeline gaps. The average deal size also increased to $3.1 billion in H1 2026, up from $2.7 billion in 2025, indicating a trend toward larger transactions.

Several major deals defined this period, with three transactions exceeding $10 billion: Sun Pharma's acquisition of Organon for $11.8 billion, AbbVie's purchase of Apogee Therapeutics for $10.9 billion, and GSK's acquisition of Nuvalent for $10.6 billion. Additionally, six deals ranged between $5 billion and $10 billion, including Gilead's $7.8 billion acquisition of Arcellx and Eli Lilly's $7.8 billion deal for Centessa. Eli Lilly stood out as the most active acquirer, deploying $26 billion across nine deals exceeding $250 million each.

Analysts from PwC and BioCentury note that the current pace suggests 2026 could eclipse 2014's all-time record of $209.3 billion in total deal value, potentially reaching over $300 billion in biopharma and services M&A. This compares to $112 billion spent on 26 blockbuster deals in 2025. The strong deal-making momentum is fueled by healthy balance sheets, ample capital, and a strategic imperative to replenish pipelines. Despite the high volume, no mega-mergers exceeding $30 billion have occurred, continuing a trend from 2024 and 2025.

The M&A surge is occurring even as the biotech IPO window has also reopened, with record-breaking listings like Kailera's $625 million IPO and Parabilis Medicines' $670 million IPO. However, investor scrutiny remains high, and many private biotech companies still face funding pressures, making M&A an attractive exit strategy. This confluence of factors points towards 2026 potentially becoming the strongest year for M&A since the pandemic, possibly exceeding $250 billion in aggregate deal value.